Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence indicates that lutetium-177 vipivotide tetraxetan shows comparable efficacy to existing options, specifically best supportive care and cabazitaxel. While it increases the time before cancer progression and overall survival compared to best supportive care, the evidence is limited by high withdrawal rates in the trials and uncertainty in the comparative effectiveness against cabazitaxel. The committee noted that the evidence for lutetium-177 compared to cabazitaxel is uncertain due to limitations in the indirect comparisons.
Cost effectiveness
The cost-effectiveness estimates for lutetium-177 are above what NICE typically considers acceptable, even when accounting for end-of-life criteria. The committee noted that the ICERs presented were considerably higher than the thresholds usually accepted for Healthcare resources, indicating low cost-effectiveness.
Quality of life
The evidence suggests that lutetium-177 may improve quality of life compared to cabazitaxel, with fewer severe adverse events reported. Patient and clinical expert feedback indicated that patients experienced fewer side effects and maintained a better quality of life while on lutetium-177 compared to traditional chemotherapy options. However, the utility estimates remain uncertain due to the variability in patient experiences and the methodology used in the analyses.
Supporting Domains
Safety and Adverse Effects
Lutetium-177 is reported to have a good safety profile with manageable adverse effects compared to traditional chemotherapy. The clinical experts noted that while there are treatment-emergent adverse events, they are generally less severe than those associated with taxane-based therapies, suggesting that it is well tolerated.
Comparator Selection
The primary comparators used in the evidence were cabazitaxel and best supportive care. While cabazitaxel is relevant, the exclusion of radium-223 dichloride as a comparator limits the robustness of the evidence. The committee noted that the lack of direct comparative evidence against radium-223 dichloride is a significant gap.
Patient Population and Subgroups
The trial population appears to be broadly representative of the intended patient population, with relevant subgroup analyses conducted. However, there is a noted lack of evidence for patients for whom taxanes are ‘medically unsuitable’, which introduces some limitations.
Care Pathway Integration
Lutetium-177 is positioned appropriately within the treatment pathway for hormone-relapsed metastatic prostate cancer. The committee noted that it could be integrated into existing treatment protocols with minor adjustments, particularly in terms of PSMA imaging requirements.
Resource Use and Cost Implications
The resource implications of implementing lutetium-177 are significant, particularly due to the high costs associated with the treatment and the necessary imaging for patient eligibility. The committee expressed concerns about the overall budget impact, which may require restrictions.
Evidence Quality and Robustness
The evidence base includes a Phase 3 trial (VISION) but is limited by high withdrawal rates and uncertainties in the indirect comparisons. While the trial design is robust, the overall quality of evidence is affected by these limitations, necessitating further data for more definitive conclusions.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the cost-effectiveness and clinical effectiveness of lutetium-177, particularly in its comparison with cabazitaxel. The committee noted that these uncertainties could impact its broader acceptance and use within the Healthcare.
